Quantbot Technologies LP Mirati Therapeutics, Inc. Transaction History

Quantbot Technologies LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$36.54 - $54.26 $97,123 - $144,223	2,658 New	2,658 $98,000
Q3 2021 Nov 09, 2021	SELL	$132.13 - $177.45 $16,780 - $22,536	-127 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$144.0 - $179.73 $119,232 - $148,816	-828 Reduced 86.7%	127 $20,000
Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $86,611 - $120,777	-545 Reduced 36.33%	955 $163,000
Q4 2020 Feb 12, 2021	SELL	$162.05 - $240.27 $76,325 - $113,167	-471 Reduced 23.9%	1,500 $329,000
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $223,235 - $329,689	1,971 New	1,971 $327,000
Q4 2019 Feb 10, 2020	SELL	$70.76 - $128.86 $21,228 - $38,658	-300 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$77.91 - $109.6 $7,791 - $10,960	-100 Reduced 25.0%	300 $23,000
Q2 2019 Aug 13, 2019	BUY	$59.49 - $104.71 $23,796 - $41,884	400 New	400 $41,000
Q3 2018 Nov 13, 2018	SELL	$47.1 - $62.7 $22,137 - $29,469	-470 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$26.05 - $52.4 $121,236 - $243,869	-4,654 Reduced 90.83%	470 $23,000
Q1 2018 May 11, 2018	BUY	$17.2 - $34.95 $88,132 - $179,083	5,124 New	5,124 $157,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.